Cabozantinib
| CAS No. | 849217-68-1 |
|---|---|
| MDL No. | MFCD20926324 |
| MF | C28H24FN3O5 |
| MW | 501.50 |
| InChI Key | ONIQOQHATWINJY-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Cabozantinib is a dicarboxylic acid diamide, specifically N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide with the hydrogen at position 4 of the phenyl ring replaced by a (6,7-dimethoxyquinolin-4-yl)oxy group. It is a multi-tyrosine kinase inhibitor used as its malate salt in the treatment of progressive, metastatic medullary thyroid cancer. It functions as a tyrosine kinase inhibitor and antineoplastic agent, and is classified as a quinoline, organofluorine compound, aromatic ether, and dicarboxylic acid diamide.
| CAS No. | 849217-68-1 |
|---|---|
| Product Name | Cabozantinib |
Biological Targets
MET·KDR
Associated Conditions
ovarian carcinoma·soft tissue sarcoma·follicular thyroid carcinoma·colon adenocarcinoma·urothelial carcinoma·
* The information provided here is compiled from public sources and is for reference only.
